News & Analysis on Clinical Trial Services & Contract Research And Development
Recordati is expecting to sell off its pharmaceutical chemical operations by the end of next year or early in 2004, according to the company's chief executive, who expects €80-€90m in proceeds for the sale.
Millions of dollars are being spent unnecessarily each year on treatments for high blood pressure says research published this week in BMC Health Services Research.
An October conference on biogenerics will see research-based biopharmaceutical companies and their generic rivals battle to win the hearts and minds of regulators.
Medical device multinational Guidant has paid $35 million (€32m) in cash to acquire the rights to a polymer technology from MediVas for use in its stent programme.
UK pharmaceutical manufacturing and distribution company Intercare has posted a record set of results for the first half of 2003.
Wacker has officially inaugurated its new fumed-silica production facilities in Nünchritz, boosting its capacity by around a third.